Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Down 6.7% – Time to Sell?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)’s share price traded down 6.7% during trading on Wednesday . The company traded as low as $0.26 and last traded at $0.27. 32,941,376 shares changed hands during mid-day trading, a decline of 51% from the average session volume of 67,884,172 shares. The stock had previously closed at $0.29.

Analyst Upgrades and Downgrades

Separately, StockNews.com assumed coverage on Tonix Pharmaceuticals in a research report on Wednesday, January 1st. They set a “hold” rating on the stock.

Tonix Pharmaceuticals Stock Performance

The firm has a 50-day moving average price of $0.24 and a two-hundred day moving average price of $0.33. The company has a quick ratio of 2.81, a current ratio of 3.33 and a debt-to-equity ratio of 0.07. The firm has a market cap of $49.45 million, a PE ratio of -0.01 and a beta of 2.02.

Tonix Pharmaceuticals (NASDAQ:TNXP) last released its earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. The firm had revenue of $2.82 million during the quarter, compared to analyst estimates of $2.63 million. Research analysts forecast that Tonix Pharmaceuticals Holding Corp. will post -17.63 EPS for the current fiscal year.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.